Treatment of SpA – update from EULAR
At this year’s EULAR congress, several new interesting data for the treatment of SpA were presented, where especially IL-23 inhibition provided some interesting data. Inhibition of JAK-STAT also shows great results – also in real-world studies. As you can hear in this MEDtalk, there are also drugs with new mode of action on the way. All studies have been selected by Lars Erik Kristensen, Head of Research, Parker Institute, specialist in internal medicine and rheumatology. Hear his perspective on the new data in this MEDtalk.
Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.